Alpine Immune Sciences (Nasdaq:ALPN) - Hisse Senedi Fiyatı, Haberler ve Analizler

ALPN Stoklara Genel Bakış

Operates as a clinical-stage biopharmaceutical company. Daha fazla detay

ALPN temel anali̇z
Kar Tanesi Skoru
Değerleme	1/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	6/6
Temettüler	0/6

Ödüller

Gelirin yılda 34.24% oranında artması öngörülüyor

Risk Analizi

Önümüzdeki 3 yıl boyunca kazançların yılda ortalama 9.9% oranında düşmesi öngörülüyor

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

Hissedarlar geçen yıl sulandırıldı

Son 3 ayda dalgalı hisse senedi fiyatı

Alpine Immune Sciences, Inc. Rakipler

Halozyme Therapeutics

NasdaqGS:HALO

US$6.2b

Blueprint Medicines

NasdaqGS:BPMC

US$6.0b

Turning Point Therapeutics

NasdaqGS:TPTX

US$3.8b

Alkermes

NasdaqGS:ALKS

US$4.7b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Alpine Immune Sciences
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$64.97
52 Haftanın En Yüksek Seviyesi	US$65.00
52 Haftanın En Düşük Seviyesi	US$8.33
Beta	0.97
11 Aylık Değişim	0.65%
3 Aylık Değişim	113.79%
1 Yıllık Değişim	518.17%
33 Yıllık Değişim	520.53%
5 Yıllık Değişim	1,270.68%
Halka arzdan bu yana değişim	580.31%

Son Haberler & Güncellemeler

Recent updates

Alpine: Vertex Acquisition Brings About More Than IgA Nephropathy Advancement

Apr 11

Earnings Update: Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Just Reported And Analysts Are Trimming Their Forecasts

Mar 21

Here's Why We're Not Too Worried About Alpine Immune Sciences' (NASDAQ:ALPN) Cash Burn Situation

Mar 20

Alpine Immune Sciences: Track Record Undermines Case For Latest Lead Drug

Mar 07

Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) Shares Climb 41% But Its Business Is Yet to Catch Up

Feb 07

Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) 41% Share Price Surge Not Quite Adding Up

Dec 19

We Think Alpine Immune Sciences (NASDAQ:ALPN) Can Afford To Drive Business Growth

Sep 23

Despite Lacking Profits Alpine Immune Sciences (NASDAQ:ALPN) Seems To Be On Top Of Its Debt

Aug 09

Alpine: Rest Before Rallying Again

Apr 25

Is Alpine Immune Sciences (NASDAQ:ALPN) A Risky Investment?

Apr 12

Rock star Growth Puts Alpine Immune Sciences (NASDAQ:ALPN) In A Position To Use Debt

Sep 18

Industry Analysts Just Upgraded Their Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Revenue Forecasts By 42%

Aug 18

Hissedar Getirileri

	ALPN	US Biotechs	US Pazar
7D	0.03%	2.5%	2.2%
1Y	518.2%	16.1%	31.6%

Getiri vs. Endüstri: ALPN geçen yıl % 16.1 oranında getiri sağlayan US Biotechs sektörünü aştı.

Getiri vs Piyasa: ALPN geçen yıl % 31.6 oranında getiri sağlayan US Piyasasını aştı.

Fiyat Oynaklığı

Is ALPN's price volatile compared to industry and market?
ALPN volatility
ALPN Average Weekly Movement	13.8%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: ALPN hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: ALPN 'nin haftalık oynaklığı ( 14% ) geçen yıl boyunca sabit kaldı, ancak hala US hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2007	142	Mitch Gold	www.alpineimmunesciences.com

Alpine Immune Sciences, Inc. Temel Bilgiler Özeti

Alpine Immune Sciences'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
ALPN temel i̇stati̇sti̇kler
Piyasa değeri	US$4.46b
Kazançlar(TTM)	-US$36.84m
Gelir(TTM)	US$56.52m

78.9x

P/S Oranı

-121.0x

F/K Oranı

ALPN aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
ALPN gelir tablosu (TTM)
Gelir	US$56.52m
Gelir Maliyeti	US$83.78m
Brüt Kâr	-US$27.26m
Diğer Giderler	US$9.58m
Kazançlar	-US$36.84m

Son Raporlanan Kazançlar

Mar 31, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.54
Brüt Marj	-48.23%
Net Kâr Marjı	-65.17%
Borç/Özkaynak Oranı	0%

ALPN uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

ALPN Stoklara Genel Bakış

Ödüller

Risk Analizi

Alpine Immune Sciences, Inc. Rakipler

NasdaqGS:HALO

US$6.2b

NasdaqGS:BPMC

US$6.0b

NasdaqGS:TPTX

US$3.8b

NasdaqGS:ALKS

US$4.7b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Alpine Immune Sciences Files Form 15

Alpine Immune Sciences, Inc.(NasdaqGM:ALPN) dropped from NASDAQ Composite Index

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) completed the acquisition of Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) from a group of shareholders.

Alpine Immune Sciences, Inc.(NasdaqGM:ALPN) dropped from S&P TMI Index

Consensus estimates of losses per share improve by 20%

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Recent updates

Alpine Immune Sciences Files Form 15

Alpine Immune Sciences, Inc.(NasdaqGM:ALPN) dropped from NASDAQ Composite Index

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) completed the acquisition of Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) from a group of shareholders.

Alpine Immune Sciences, Inc.(NasdaqGM:ALPN) dropped from S&P TMI Index

Consensus estimates of losses per share improve by 20%

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) entered into an agreement to acquire Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) from a group of shareholders for approximately $4.3 billion.

Alpine: Vertex Acquisition Brings About More Than IgA Nephropathy Advancement

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) entered into an agreement to acquire Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) from a group of shareholders for approximately $4.3 billion.

New minor risk - Share price stability

Alpine Immune Sciences, Inc Presents New Translational Data on Povetacicept at the European Lupus Meeting 2024

Earnings Update: Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Just Reported And Analysts Are Trimming Their Forecasts

Here's Why We're Not Too Worried About Alpine Immune Sciences' (NASDAQ:ALPN) Cash Burn Situation

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Price target increased by 10% to US$37.00

Alpine Immune Sciences, Inc. to Report Fiscal Year 2023 Results on Mar 18, 2024

Alpine Immune Sciences: Track Record Undermines Case For Latest Lead Drug

Price target increased by 9.5% to US$33.57

Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) Shares Climb 41% But Its Business Is Yet to Catch Up

Price target increased by 11% to US$31.83

Price target increased by 12% to US$30.67

Executive Chairman & CEO exercised options and sold US$1.8m worth of stock

Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) 41% Share Price Surge Not Quite Adding Up

Executive Chairman & CEO notifies of intention to sell stock

Consensus revenue estimates increase by 12%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Alpine Immune Sciences, Inc. has completed a Follow-on Equity Offering in the amount of $149.9968 million.

Alpine Immune Sciences, Inc. has completed a Follow-on Equity Offering in the amount of $110 million.

Alpine Immune Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Alpine Immune Sciences, Inc. Presents Initial Clinical Data on Povetacicept in Autoimmune Glomerulonephritis

New minor risk - Share price stability

Alpine Immune Sciences, Inc. Announces Appointment of Wolfgang Dummer as Chief Medical Officer

We Think Alpine Immune Sciences (NASDAQ:ALPN) Can Afford To Drive Business Growth

Alpine Immune Sciences, Inc. Announces Initiation of Dosing in 240 mg IgA Nephropathy Cohort of Povetacicept Clinical Study (RUBY-3)

Consensus estimates of losses per share improve by 12%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Revenues Not Telling The Story For Alpine Immune Sciences, Inc. (NASDAQ:ALPN)

Full year 2022 earnings: EPS and revenues miss analyst expectations

Is Alpine Immune Sciences (NASDAQ:ALPN) Weighed On By Its Debt Load?

Consensus revenue estimates fall by 33%

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

Alpine Immune Sciences, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Consensus forecasts updated

Alpine Immune Sciences Terminates Enrollment of Davoceticept Clinical Studies (NEON-1 and NEON-2)

Price target decreased to US$18.33

Alpine Immune Sciences, Inc. has completed a Follow-on Equity Offering in the amount of $100.0041 million.

Alpine Immune Sciences, Inc. has completed a Follow-on Equity Offering in the amount of $100.0041 million.

Alpine Immune Sciences drops 13% after hours on $100M stock offering

Alpine Immune Sciences, Inc. Provides Clinical Updates for Its Two Wholly Owned Programs, ALPN-303 and davoceticept

Consensus EPS estimates fall by 22%

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Despite Lacking Profits Alpine Immune Sciences (NASDAQ:ALPN) Seems To Be On Top Of Its Debt

Alpine Immune Sciences, Inc. Announces Board Changes

Alpine Immune Sciences Appoints Andrew S. Sandler as Chief Medical Officer

Alpine Immune Sciences, Inc. Announces Update on ALPN-303, a Dual BAFF/APRIL Inhibitor for Systemic Lupus Erythematosus and Other Autoimmune and Inflammatory Diseases, at EULAR 2022

Alpine Immune Sciences, Inc. Announces FDA Removes Partial Clinical Hold on NEON-2 Clinical Trial of Davoceticept (ALPN-202) in Combination with Pembrolizumab

Alpine Immune Sciences, Inc. Announces FDA Removes Partial Clinical Hold on NEON-2 Clinical Trial of Davoceticept (ALPN-202) in Combination with Pembrolizumab